Femasys (FEMY) AI Stock Analysis

• Market Cap: $27.24M
• Dividend Yield: N/A
• Average Volume (3M): 9.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 98.61%
• EPS Growth: -1.98%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.16
• Shares Outstanding: 43,009,995
• 10 Day Avg. Volume: 14,240,575
• 30 Day Avg. Volume: 9,459,675
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 17.24
• Enterprise Value/Gross Profit: 32.10
• Enterprise Value/Ebitda: -1.77
• 1Y Price Target: $5.50
• Price Target Upside: 773.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: $0.50 ▼(-20.63% Downside)

Femasys faces significant financial challenges with persistent losses and cash flow issues, which heavily weigh down its overall score. While there is some positive technical momentum, the lack of profitability and unattractive valuation metrics further impact the stock's attractiveness.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for Femasys's innovative medical devices, suggesting potential for market expansion and increased adoption of its products in women's reproductive health.

Innovative Product Offering

Femasys's focus on innovative, non-surgical reproductive health solutions positions it well in the market, catering to the growing demand for accessible and effective women's health treatments.

Market Expansion Potential

Strategic partnerships and collaborations can enhance Femasys's market reach, allowing it to leverage larger networks and increase product visibility, which is crucial for long-term growth.

Negative Factors

Financial Instability

Ongoing financial instability, marked by persistent losses, poses a risk to Femasys's sustainability. Addressing these issues is critical to ensuring long-term viability and operational success.

Negative Cash Flow

Negative cash flows highlight operational challenges and reliance on external financing, which can limit Femasys's ability to invest in growth initiatives and maintain financial flexibility.

High Leverage

High leverage increases financial risk, potentially impacting Femasys's ability to manage debt obligations and invest in future growth, necessitating careful financial management.

Femasys Business Overview & Revenue Model

Company Description

Femasys (FEMY) is a biotechnology company focused on advancing women's health by developing innovative medical devices and solutions for reproductive health. The company operates primarily in the healthcare sector, specializing in products that address various aspects of female fertility and contraception. Femasys's core offerings include its proprietary systems for non-surgical treatment options, which aim to improve accessibility and effectiveness for women seeking reproductive health solutions.

How the Company Makes Money

Femasys generates revenue primarily through the sale of its medical devices and systems designed for women's reproductive health. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics that utilize its innovative technologies. Additionally, Femasys may engage in partnerships with other healthcare organizations and distributors to expand its market reach and enhance product visibility. Key revenue streams include product sales from its core offerings and potential licensing agreements or collaborations with larger medical companies that can leverage Femasys's technology in broader applications. The company may also benefit from grants or funding aimed at supporting women's health initiatives, further contributing to its financial performance.

Femasys Financial Statement Overview

Summary

Femasys is facing significant financial challenges, with persistent losses and negative cash flows. Despite some revenue growth, the company struggles with operational inefficiencies and financial instability, requiring urgent improvements in financial health and profitability.

Income Statement

Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.

Balance Sheet

The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.

Cash Flow

Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.89M	1.63M	1.07M	1.21M	1.18M	1.04M
Gross Profit	1.01M	1.08M	691.90K	764.28K	809.30K	731.38K
EBITDA	-18.34M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
Net Income	-21.02M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet
Total Assets	2.43M	12.45M	27.76M	16.90M	28.58M	7.61M
Cash, Cash Equivalents and Short-Term Investments	3.22M	3.45M	21.72M	12.96M	24.78M	3.32M
Total Debt	7.85M	7.44M	6.70M	543.72K	990.21K	2.06M
Total Liabilities	12.27M	10.14M	9.40M	1.65M	2.24M	59.42M
Stockholders Equity	1.51M	2.30M	18.35M	15.24M	26.33M	-51.82M
Cash Flow
Free Cash Flow	-20.41M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
Operating Cash Flow	-19.67M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
Investing Cash Flow	-744.21K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
Financing Cash Flow	10.10M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.63
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Positive. The current price of 0.63 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 0.49, and below the 200-day MA of 0.97, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 54.14 is Neutral, neither overbought nor oversold. The STOCH value of 22.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	58 Neutral	$7.10M	0.72	5.90%	―	-4.99%	-19.11%
RVP	53 Neutral	$28.47M	-3.17	-10.80%	―	-0.24%	50.45%
NXGL	53 Neutral	$27.70M	―	-66.08%	―	133.00%	29.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	45 Neutral	$27.24M	-0.73	-329.45%	―	98.61%	-1.98%
POCI	41 Neutral	$33.17M	-5.06	-51.78%	―	-0.07%	-74.60%
MLSS	41 Neutral	$32.10M	-4.70	-123.50%	―	7.84%	-43.00%

Femasys Corporate Events

Femasys Meets Nasdaq Equity Requirement After Offering

On May 19, 2025, Femasys Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum market value requirement for continued listing. However, after a recent offering and warrant exercises, the company reported a pro forma stockholders’ equity of approximately $5.2 million as of October 15, 2025, meeting Nasdaq’s minimum requirement. Nasdaq will continue to monitor Femasys’ compliance, and failure to maintain these standards could result in delisting.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys COO Daniel Currie Announces Retirement

On October 13, 2025, Daniel Currie, Chief Operating Officer of Femasys Inc., announced his retirement effective December 15, 2025, after over 20 years with the company. His departure is due to personal health reasons and a desire to focus on family. The company has entered into a Separation Agreement with Currie, ensuring the vesting of unvested stock options and continuation of health benefits through 2026. The Board of Directors expressed their gratitude for his leadership and service.

The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Announces $8 Million Public Offering

On August 25, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC and Laidlaw & Company (UK) Ltd. for a public offering of shares and warrants, expecting to raise $8 million. The proceeds will be used for commercial expansion, product development, and general corporate purposes, with the offering set to close on August 27, 2025.

The most recent analyst rating on (FEMY) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Gains UK Approval for FemBloc Birth Control

On August 20, 2025, Femasys Inc. announced that it received UK regulatory approval for its FemBloc Permanent Birth Control, a non-surgical solution for permanent birth control. This approval marks a significant milestone in Femasys’ European commercialization strategy, following its recent CE mark for Europe. The approval not only validates FemBloc’s safety and effectiveness but also positions Femasys to secure a strategic partner for commercialization in the UK, a key healthcare market in Europe.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Femasys Enters European Market with Major Spain Order

On August 6, 2025, Femasys Inc. announced its first commercial entry into Europe with a $400,000 order for FemBloc Permanent Birth Control in Spain, marking a strategic milestone in its global expansion. FemBloc, a revolutionary non-surgical permanent contraceptive, offers a less invasive and cost-effective alternative to traditional methods, and its introduction in Spain is supported by partnerships with Comercial Medico Quirúrgica and Durgalab. This development is expected to enhance Femasys’s market positioning and meet growing demand across Europe.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.